VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) received a NYSE American notice dated February 6, 2026, that it is not in compliance with stockholders' equity listing standards in Sections 1003(a)(i)-(iii).
The company must file a compliance Plan by March 8, 2026 to regain compliance by August 6, 2027, or face potential delisting proceedings; shares will trade with a ".BC" designation meanwhile.
Positive
- Shares remain listed and tradable on NYSE American during review
- Deadline to submit a compliance plan: March 8, 2026
- Compliance cure period extends through August 6, 2027
Negative
- Non-compliance with equity thresholds of $2M, $4M, and $6M
- Shares will carry a ".BC" below-compliance designation
- Risk of delisting if plan not accepted or compliance not met
News Market Reaction – VNRX
On the day this news was published, VNRX declined 3.05%, reflecting a moderate negative market reaction. Argus tracked a peak move of +26.1% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $976K from the company's valuation, bringing the market cap to $31M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VNRX was modestly down (-0.4%) while key peers were mixed: APYX and LUNG showed gains, TELA was down, and ICCM and CTSO saw smaller moves. Only 1 peer appeared in the momentum scanner, supporting a stock-specific narrative around the NYSE American non-compliance notice.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Clinical data update | Positive | -4.5% | Sponsored HS symposium presenting Nu.Q® NETs clinical data and market opportunity. |
| Jan 30 | Reimbursement planning | Positive | +13.5% | Preparing French reimbursement submission for Nu.Q® Cancer assays with HCL support. |
| Jan 27 | New indication data | Positive | -0.2% | Nu.Q® NETs study supporting use in Hidradenitis Suppurativa and TAM disclosure. |
| Jan 20 | Vet test expansion | Positive | +8.4% | New lab partnerships to broaden Nu.Q® Vet Cancer Test access in US and Asia. |
| Jan 16 | Conference sponsorship | Positive | +0.6% | Sponsoring VMX symposium to promote Nu.Q® Vet Cancer Test in clinical practice. |
Recent fundamentally positive news often produced gains, but there were notable selloffs or flat reactions, indicating inconsistent alignment between news flow and price.
Over the past month, VolitionRx announced several product and clinical milestones, including new Nu.Q® Vet Cancer Test distribution deals and Nu.Q® NETs data in Hidradenitis Suppurativa, with cited total addressable markets up to $3.8 billion. Reimbursement preparation in France on Jan 30 saw a 13.5% rise, while some scientific updates around Jan 27 and Feb 4 drew mild or negative reactions. Against this backdrop of mixed price responses to generally positive operating news, today’s NYSE American non-compliance notice introduces a distinctly regulatory and listing-risk dimension.
Regulatory & Risk Context
An effective S-3 shelf was filed on Feb 9, 2026, registering 17,968,090 existing-investor shares for resale, including shares tied to a secured convertible note and warrants. The company receives no proceeds from these sales, but large secondary transactions over time could add share overhang alongside the NYSE American non-compliance status.
Market Pulse Summary
This announcement highlights heightened listing risk, as VNRX fell short of NYSE American equity thresholds tied to multi-year losses and failed to qualify for the $50 million market-cap exemption. The company must submit a remediation plan by March 8, 2026 and regain compliance by August 6, 2027, while its stock already trades below the $0.50 200-day MA and well under its 52-week high. Investors may track progress on the NYSE plan alongside potential impacts from 17,968,090 registered resale shares.
Key Terms
nyse american regulatory
continued listing standards regulatory
delisting proceedings regulatory
u.s. securities and exchange commission regulatory
AI-generated analysis. Not financial advice.
In connection with its non-compliance with Section 1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii), the Company must submit a plan (the "Plan") to the NYSE American by March 8, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards by August 6, 2027. If the NYSE American determines to accept the Plan, the Company will be notified in writing and will be subject to periodic reviews, including quarterly monitoring for compliance with the Plan. If the Company does not submit a plan or if the Plan is not accepted, NYSE American will commence delisting proceedings. Furthermore, if the Plan is accepted but the Company is not in compliance with the continued listing standards by August 6, 2027 or if the Company does not make progress consistent with the Plan, the NYSE American will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.
The Notice has no immediate impact on the listing of the Company's shares of common stock, which will continue to be listed and traded on the NYSE American during this period, subject to the Company's compliance with the other listing requirements of the NYSE American. The common stock will continue to trade under the symbol "VNRX", but will have an added designation of ".BC" to indicate the status of the common stock are "below compliance". The Notice does not affect the Company's ongoing business operations or its reporting requirements with the
The Company is committed to achieving compliance with the NYSE American's requirements and intends to submit a plan to the NYSE American on or before March 8, 2026 that will regain compliance with the NYSE American continued listing standards by August 6, 2027. However, there can be no assurance that the Company will be able to achieve compliance with the NYSE American's continued listing standards within the required timeframe.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life- altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the
Media Enquiries
Louise Batchelor, Volition mediarelations@volition.com
+44 (0)7557 774620
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the Company's expectations surrounding the submission of a plan and regaining compliance with the NYSE American's continued listing standards, and actions of the Company and/or the NYSE American to be taken with respect to matters discussed in the Notice. . All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Volition believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct.
Forward-looking statements are subject to risks and uncertainties that may cause Volition's actual activities or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties related to the Company's ability to timely submit its plan to the NYSE American, the acceptance of its plan by the NYSE American and the Company's ability to regain compliance with the listing standards set forth in the Company Guide by August 6, 2027, as well as the risks disclosed in other documents Volition files from time to time with the SEC, including Volition's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
View original content:https://www.prnewswire.com/news-releases/volitionrx-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-302683021.html
SOURCE VolitionRx Limited
FAQ
What did VolitionRx (VNRX) receive from NYSE American on February 6, 2026?
What deadlines must VolitionRx (VNRX) meet after the NYSE notice?
Will VolitionRx (VNRX) shares stay listed while the company addresses non-compliance?
What listing standards did VolitionRx (VNRX) fail to meet under the NYSE American rules?
What are the consequences if VolitionRx (VNRX) does not regain compliance with NYSE American?
